Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
22 08 2019
Historique:
received: 22 04 2019
accepted: 11 07 2019
entrez: 23 8 2019
pubmed: 23 8 2019
medline: 18 9 2020
Statut: epublish

Résumé

The synucleinopathies Parkinson's disease (PD) and Multiple system atrophy (MSA) - characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and oligodendrocytes - are associated with impairment of the autophagy-lysosomal pathways (ALP). Increased expression of the master regulator of ALP, transcription factor EB (TFEB), is hypothesized to promote the clearance of WT α-synuclein and survival of dopaminergic neurons. Here, we explore the efficacy of targeted TFEB overexpression either in neurons or oligodendrocytes to reduce the pathological burden of α-synuclein in a PD rat model and a MSA mouse model. While TFEB neuronal expression was sufficient to prevent neurodegeneration in the PD model, we show that only TFEB oligodendroglial overexpression leads to neuroprotective effects in the MSA model. These beneficial effects were associated with a decreased accumulation of α-synuclein into oligodendrocytes through recovery of the ALP machinery. Our study demonstrates that the cell type where α-synuclein aggregates dictates the target of TFEB overexpression in order to be protective, paving the way for adapted therapies.

Identifiants

pubmed: 31434803
pii: 129719
doi: 10.1172/jci.insight.129719
pmc: PMC6777809
doi:
pii:

Substances chimiques

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors 0
TFEB protein, human 0
TFEB protein, rat 0
Tcfeb protein, mouse 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Science. 2004 Aug 27;305(5688):1292-5
pubmed: 15333840
J Neurosci. 2011 Oct 12;31(41):14508-20
pubmed: 21994367
Stem Cell Reports. 2018 Nov 13;11(5):1185-1198
pubmed: 30344007
Ann Neurol. 2013 Jul;74(1):140-4
pubmed: 23494678
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Acta Neuropathol Commun. 2015 Jul 25;3:46
pubmed: 26205255
Dig Med Res. 2018 Sep;1:null
pubmed: 30450489
J Mol Neurosci. 2012 Jun;47(2):256-66
pubmed: 22411133
Auton Neurosci. 2018 May;211:1-6
pubmed: 29169744
Autophagy. 2019 Mar;15(3):493-509
pubmed: 30304977
J Neurosci. 2010 Sep 15;30(37):12535-44
pubmed: 20844148
Neurobiol Dis. 2013 Jan;49:190-8
pubmed: 22959883
Nat Commun. 2018 Aug 17;9(1):3312
pubmed: 30120233
EMBO Rep. 2002 Jun;3(6):583-8
pubmed: 12034752
Ann Neurol. 2014 Mar;75(3):351-62
pubmed: 24243558
Hum Gene Ther Methods. 2012 Feb;23(1):18-28
pubmed: 22428977
Oncogene. 2008 Oct 27;27(50):6434-51
pubmed: 18955971
Cell Death Dis. 2018 Aug 28;9(9):858
pubmed: 30154423
PLoS One. 2015 Mar 19;10(3):e0120819
pubmed: 25790376
Neurosci J. 2016;2016:4732837
pubmed: 27433468
EMBO J. 2012 Mar 7;31(5):1095-108
pubmed: 22343943
Front Neuroanat. 2014 Aug 14;8:83
pubmed: 25177278
Science. 2017 Jun 16;356(6343):1188-1192
pubmed: 28619945
J Neurosci. 2008 Jul 9;28(28):7174-83
pubmed: 18614687
Synapse. 2014 Mar;68(3):98-106
pubmed: 24243499
Neurobiol Dis. 2019 Feb;122:83-93
pubmed: 29852219
Hum Mol Genet. 2011 Oct 1;20(19):3852-66
pubmed: 21752829
Brain. 2017 May 1;140(5):1420-1436
pubmed: 28334990
Mol Neurobiol. 2013 Apr;47(2):537-51
pubmed: 22941029
J Biol Chem. 2014 Apr 4;289(14):10211-22
pubmed: 24558044
Sci Rep. 2019 Jan 24;9(1):727
pubmed: 30679718
Brain. 2013 Jul;136(Pt 7):2130-46
pubmed: 23757764
J Clin Invest. 2008 Feb;118(2):777-88
pubmed: 18172548
Mol Ther. 2018 Jun 6;26(6):1552-1567
pubmed: 29628303
Neurobiol Dis. 2014 Jul;67:133-9
pubmed: 24727096
Trends Neurosci. 2016 Apr;39(4):221-234
pubmed: 26968346
BMC Neurosci. 2018 May 21;19(1):32
pubmed: 29783943
Neurobiol Dis. 2019 Feb;122:94-105
pubmed: 29859318
PLoS One. 2015 Aug 28;10(8):e0136769
pubmed: 26317353
J Neurosci. 2004 Feb 25;24(8):1888-96
pubmed: 14985429
Autophagy. 2007 Nov-Dec;3(6):663-6
pubmed: 17622797
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9593-8
pubmed: 27482103
Nat Rev Drug Discov. 2018 Sep;17(9):660-688
pubmed: 30116051
J Neurosci. 2009 Oct 28;29(43):13578-88
pubmed: 19864570
J Exp Med. 2018 Sep 3;215(9):2355-2377
pubmed: 30108137
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Commun. 2019 Mar 7;10(1):973
pubmed: 30846695
Proc Natl Acad Sci U S A. 2013 May 7;110(19):E1817-26
pubmed: 23610405
Acta Neuropathol Commun. 2018 Jan 3;6(1):2
pubmed: 29298733
Science. 2011 Jun 17;332(6036):1429-33
pubmed: 21617040
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12053-E12062
pubmed: 30509990
Autophagy. 2011 Jan;7(1):98-100
pubmed: 21045565
Acta Neuropathol. 2010 Jan;119(1):37-53
pubmed: 19847447
EMBO Mol Med. 2013 May;5(5):691-706
pubmed: 23606558
Hum Mol Genet. 2013 May 15;22(10):1994-2009
pubmed: 23393155
Lancet Neurol. 2018 Sep;17(9):802-815
pubmed: 30129476
Autophagy. 2018;14(9):1646-1648
pubmed: 29969942
EMBO J. 2018 Jun 1;37(11):
pubmed: 29764979
Gene Ther. 1999 Jun;6(6):973-85
pubmed: 10455399
J Biol Chem. 2008 Aug 29;283(35):23542-56
pubmed: 18566453
Ageing Res Rev. 2016 Dec;32:140-149
pubmed: 26947123
Exp Neurol. 2016 Sep;283(Pt B):501-11
pubmed: 26957369
Lancet Neurol. 2015 Aug;14(8):855-866
pubmed: 26050140
J Neurosci. 2006 Apr 26;26(17):4481-91
pubmed: 16641227
Anal Biochem. 1987 Apr;162(1):156-9
pubmed: 2440339

Auteurs

Marie-Laure Arotcarena (ML)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Mathieu Bourdenx (M)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Nathalie Dutheil (N)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Marie-Laure Thiolat (ML)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Evelyne Doudnikoff (E)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Sandra Dovero (S)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Andrea Ballabio (A)

Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli (Naples), Italy.
Department of Translational Medicine, Federico II University, Naples, Italy.
Department of Molecular and Human Genetics, Ian and Dan Duncan Neurological Research Institute, Baylor College of Medicine, Houston, Texas, USA.

Pierre-Olivier Fernagut (PO)

Laboratoire de Neurosciences Expérimentales et Cliniques, INSERM U-1084, Université de Poitiers, Poitiers, France.

Wassilios G Meissner (WG)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
Service de Neurologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Erwan Bezard (E)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Benjamin Dehay (B)

Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.
CNRS, Institut des Maladies Neurodégénératives, UMR 5293, F-33000 Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH